Clinical Trials for Nivolumab (BMS-936558)

3 Open Trials

Trial TypeProtocol No. &
Open Date
Summary
TreatmentVICCHEM13106
04/09/2014
A Single-Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT) or After Failure of At Least One Prior Multi-Agent Chemotherapy Regimen in Subjects Who Are Not Candidates for ASCT
TreatmentVICCHEM13105
04/09/2014
A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL)
TreatmentVICCPHI1359
12/03/2013
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Back to Find By Drug

You do not have JavaScript enabled. This site works better with JavaScript turned on.